Stocks and Investing Stocks and Investing
Fri, October 13, 2023
Thu, October 12, 2023

Eliana Merle Maintained (AKRO) at Strong Buy with Decreased Target to $39 on, Oct 12th, 2023


Published on 2024-10-28 06:52:11 - WOPRAI, Eliana Merle
  Print publication without navigation


Eliana Merle of UBS, Maintained "Akero Therapeutics, Inc." (AKRO) at Strong Buy with Decreased Target from $83 to $39 on, Oct 12th, 2023.

Eliana has made no other calls on AKRO in the last 4 months.



There are 5 other peers that have a rating on AKRO. Out of the 5 peers that are also analyzing AKRO, 0 agree with Eliana's Rating of Hold.



These are the ratings of the 5 analyists that currently disagree with Eliana


  • Ed Arce of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $40 on, Wednesday, October 11th, 2023
  • Eric Joseph of "JP Morgan" Maintained at Buy with Decreased Target to $41 on, Wednesday, October 11th, 2023
  • Michael Ulz of "Morgan Stanley" Maintained at Buy with Decreased Target to $33 on, Wednesday, October 11th, 2023
  • Prakhar Agrawal of "Cantor Fitzgerald" Maintained at Buy with Decreased Target to $39 on, Wednesday, October 11th, 2023
  • Liisa Bayko of "Evercore ISI Group" Maintained at Buy with Increased Target to $60 on, Wednesday, September 13th, 2023

Contributing Sources